AnaptysBio, Inc. (ANAB) Dividend History

Company News

• Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight

  The psoriasis pipeline has several drugs in mid- and late-stage development, including Imsidolimab, TAK-279, and Sonelokimab, which are expected to positively impact the market. The treatment landscape is expanding with new therapies from various companies.

  GlobeNewswire Inc.

  Featured Companies: MLTX
• Why AnaptysBio Was Such a Healthy Stock This Week

  AnaptysBio, a clinical-stage biotech company, has seen its stock price rise recently. A positive research note from Guggenheim analyst Yatin Suneja, who reiterated a buy rating and $75 price target, cites an upcoming phase 2 clinical trial readout for the company's atopic dermatitis drug and Sanofi's financial involvement as reasons for optimism.

  The Motley Fool
• Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

  AnaptysBio, a clinical-stage biotechnology company, announced the pricing of a $100 million underwritten offering of its common stock. The offering was led by existing investor EcoR1 Capital and included participation from new and existing investors, including Sanofi.

  GlobeNewswire Inc.
• Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?

  Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

  Zacks Investment Research

  Featured Companies: RGEN
• The Analyst Landscape: 7 Takes On AnaptysBio

  In the preceding three months, 7 analysts have released ratings for AnaptysBio (NASDAQ:ANAB), presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 4 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 2 0 0 0 2M Ago 0 0 1 0 0 3M Ago 2 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for AnaptysBio, presenting an average target of $50.0, a high estimate of $80.00, and a low estimate of $28.00. Surpassing the previous average price target of $30.00, the current average has increased by 66.67%. Investigating Analyst Ratings: An Elaborate Study A comprehensive examination of how financial experts perceive AnaptysBio is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Nierengarten Wedbush Maintains Outperform $34.00 - David Risinger Leerink Partners Announces Outperform $47.00 - Derek Archila Wells Fargo Announces Overweight $56.00 - Anupam Rama JP Morgan Lowers Neutral $28.00 $30.00 Julian Harrison BTIG Announces Buy $55.00 - Alex Schwartz Stifel Announces Buy $50.00 - Yasmeen Rahimi Piper Sandler Announces Overweight $80.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AnaptysBio. This information offers a snapshot of how analysts perceive the current state of ...Full story available on Benzinga.com

  Benzinga